Listed

Puma Biotechnology, Inc.

PBYINasdaqCIK 1401667HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$56.5mRevenue, Q2 FY2026, three months to 2026-06-30$56.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 6, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$56.5mRevenue, Q2 FY2026, three months to 2026-06-30$56.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Report this figure+7.8% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin13.4%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $7.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Revenue: $56.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Report this figure+0.8 pts on a year earlier
  • Net margin14.5%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $8.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Revenue: $56.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Report this figure+3.3 pts on a year earlier
  • Diluted EPS$0.16Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Report this figure+33.3% on a year earlier
  • Free cash flow$1.6mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $1.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001437749-26-026311. Derived: 6-month figure less the 3-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001437749-26-026311. Derived: 6-month figure less the 3-month figure.Report this figure−88.5% on a year earlier

Last eight quarters

Full statements
Revenue$56.5mOperating margin 13.4%
Diluted EPS$0.16, Q2 FY2026
Free cash flow$1.6m, Q2 FY2026
Puma Biotechnology, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m80.5Revenue, Q3 FY2024, three months to 2024-09-30$80.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001437749-25-033633.Report this figure59.1Revenue, Q4 FY2024, three months to 2024-12-31$59.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001437749-26-005891. Derived: 12-month figure less the 9-month figure.Report this figure46.0Revenue, Q1 FY2025, three months to 2025-03-31$46.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001437749-26-015633.Report this figure52.4Revenue, Q2 FY2025, three months to 2025-06-30$52.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Report this figure54.5Revenue, Q3 FY2025, three months to 2025-09-30$54.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001437749-25-033633.Report this figure75.5Revenue, Q4 FY2025, three months to 2025-12-31$75.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001437749-26-005891. Derived: 12-month figure less the 9-month figure.Report this figure44.8Revenue, Q1 FY2026, three months to 2026-03-31$44.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001437749-26-015633.Report this figure56.5Revenue, Q2 FY2026, three months to 2026-06-30$56.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%27.4%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $22.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001437749-25-033633.Revenue: $80.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001437749-25-033633.Report this figure22.6%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $13.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001437749-26-005891. Derived: 12-month figure less the 9-month figure.Revenue: $59.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001437749-26-005891. Derived: 12-month figure less the 9-month figure.Report this figure8.7%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $4.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001437749-26-015633.Revenue: $46.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001437749-26-015633.Report this figure12.7%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $6.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Revenue: $52.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Report this figure17.6%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $9.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001437749-25-033633.Revenue: $54.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001437749-25-033633.Report this figure22.7%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $17.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001437749-26-005891. Derived: 12-month figure less the 9-month figure.Revenue: $75.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001437749-26-005891. Derived: 12-month figure less the 9-month figure.Report this figure(8.5%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$3.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001437749-26-015633.Revenue: $44.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001437749-26-015633.Report this figure13.4%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $7.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Revenue: $56.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Report this figure
Net margin%25.2%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $20.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001437749-25-033633.Revenue: $80.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001437749-25-033633.Report this figure32.7%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $19.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001437749-26-005891. Derived: 12-month figure less the 9-month figure.Revenue: $59.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001437749-26-005891. Derived: 12-month figure less the 9-month figure.Report this figure6.5%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $3.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001437749-26-015633.Revenue: $46.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001437749-26-015633.Report this figure11.2%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $5.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Revenue: $52.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Report this figure16.2%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $8.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001437749-25-033633.Revenue: $54.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001437749-25-033633.Report this figure17.8%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $13.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001437749-26-005891. Derived: 12-month figure less the 9-month figure.Revenue: $75.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001437749-26-005891. Derived: 12-month figure less the 9-month figure.Report this figure(8.4%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001437749-26-015633.Revenue: $44.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001437749-26-015633.Report this figure14.5%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $8.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Revenue: $56.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Report this figure
Diluted EPS$ per share0.41Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001437749-25-033633.Report this figurenot reported (Diluted EPS not reported)0.06Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001437749-26-015633.Report this figure0.12Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Report this figure0.17Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001437749-25-033633.Report this figurenot reported (Diluted EPS not reported)(0.07)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001437749-26-015633.Report this figure0.16Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001437749-26-026311.Report this figure
Free cash flow$m11.0Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $11.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001437749-25-033633. Derived: 9-month figure less the 6-month figure.Capital expenditure: $20.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001437749-25-033633. Derived: 9-month figure less the 6-month figure.Report this figure15.6Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $15.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001437749-26-005891. Derived: 12-month figure less the 9-month figure.Capital expenditure: $16.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001437749-26-005891. Derived: 12-month figure less the 9-month figure.Report this figure3.6Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $3.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001437749-26-015633.Capital expenditure: $61.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001437749-26-015633.Report this figure14.1Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $14.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001437749-26-026311. Derived: 6-month figure less the 3-month figure.Capital expenditure: $20.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001437749-26-026311. Derived: 6-month figure less the 3-month figure.Report this figure9.7Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $9.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001437749-25-033633. Derived: 9-month figure less the 6-month figure.Capital expenditure: $26.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001437749-25-033633. Derived: 9-month figure less the 6-month figure.Report this figure14.4Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $14.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001437749-26-005891. Derived: 12-month figure less the 9-month figure.Capital expenditure: −$36.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001437749-26-005891. Derived: 12-month figure less the 9-month figure.Report this figure15.4Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $15.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001437749-26-015633.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001437749-26-015633.Report this figure1.6Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $1.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001437749-26-026311. Derived: 6-month figure less the 3-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001437749-26-026311. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$228.4mOperating margin 16.3%
Diluted EPS$0.61, FY2025
Free cash flow$41.7m, FY2025
Puma Biotechnology, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m253Revenue, FY2021, twelve months to 2021-12-31$253.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0001437749-24-006121.Report this figure228Revenue, FY2022, twelve months to 2022-12-31$228.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0001437749-25-005496.Report this figure236Revenue, FY2023, twelve months to 2023-12-31$235.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001437749-26-005891.Report this figure230Revenue, FY2024, twelve months to 2024-12-31$230.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001437749-26-005891.Report this figure228Revenue, FY2025, twelve months to 2025-12-31$228.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001437749-26-005891.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%0.5%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $1.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-29, accession 0001437749-24-006121.Revenue: $253.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0001437749-24-006121.Report this figure10.4%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $23.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-27, accession 0001437749-25-005496.Revenue: $228.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0001437749-25-005496.Report this figure13.9%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $32.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001437749-26-005891.Revenue: $235.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001437749-26-005891.Report this figure13.4%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $31.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001437749-26-005891.Revenue: $230.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001437749-26-005891.Report this figure16.3%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $37.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001437749-26-005891.Revenue: $228.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001437749-26-005891.Report this figure
Net margin%(11.5%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$29.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-29, accession 0001437749-24-006121.Revenue: $253.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0001437749-24-006121.Report this figure0.0%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $2.0k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-27, accession 0001437749-25-005496.Revenue: $228.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0001437749-25-005496.Report this figure9.2%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $21.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001437749-26-005891.Revenue: $235.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001437749-26-005891.Report this figure13.1%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $30.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001437749-26-005891.Revenue: $230.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001437749-26-005891.Report this figure13.6%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $31.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001437749-26-005891.Revenue: $228.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001437749-26-005891.Report this figure
Diluted EPS$ per share(0.72)Diluted EPS, FY2021, twelve months to 2021-12-31−$0.72 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-29, accession 0001437749-24-006121.Report this figure0.00Diluted EPS, FY2022, twelve months to 2022-12-31$0.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-27, accession 0001437749-25-005496.Report this figure0.45Diluted EPS, FY2023, twelve months to 2023-12-31$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001437749-26-005891.Report this figure0.62Diluted EPS, FY2024, twelve months to 2024-12-31$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001437749-26-005891.Report this figure0.61Diluted EPS, FY2025, twelve months to 2025-12-31$0.61 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001437749-26-005891.Report this figure
Free cash flow$m20.7Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $20.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-29, accession 0001437749-24-006121.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-29, accession 0001437749-24-006121.Report this figure(15.8)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$15.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-27, accession 0001437749-25-005496.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-27, accession 0001437749-25-005496.Report this figure26.9Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $27.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001437749-26-005891.Capital expenditure: $140.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001437749-26-005891.Report this figure38.9Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $38.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001437749-26-005891.Capital expenditure: $56.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001437749-26-005891.Report this figure41.7Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $41.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001437749-26-005891.Capital expenditure: $71.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001437749-26-005891.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Puma Biotechnology, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
ACORN CAPITAL ADVISORS, LLC2026-06-30$33.5m4,131,299Unchanged
BlackRock, Inc.2026-06-30$30.9m3,804,736Added+205,784
AMERICAN CENTURY COMPANIES INC2026-06-30$18.8m2,319,996Added+403,650
RENAISSANCE TECHNOLOGIES LLC2026-06-30$14.9m1,836,213Reduced−106,200
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$14.9m1,835,643Added+17,962
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$14.8m1,825,599Added+90,950
DIMENSIONAL FUND ADVISORS LP2026-06-30$12.3m1,518,014Added+81,908
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$10.9m1,339,405Added+322,063
O'SHAUGHNESSY ASSET MANAGEMENT, LLC2026-06-30$9.1m1,123,783Reduced−14,386
STATE STREET CORP2026-06-30$7.7m952,165Added+34,575

Recent filings

All 1,098 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Puma Biotechnology, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-0601:37 ETSCHEDULE 13D/AOwnership report, active investor, amended0001104659-26-114167
2026-08-0620:41 ET10-QQuarterly reportPeriod 2026-06-300001437749-26-026311
2026-08-0620:19 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001437749-26-026282
2026-06-1620:06 ET8-K5.07 Shareholder vote results0001437749-26-020793
2026-05-0720:41 ET10-QQuarterly reportPeriod 2026-03-310001437749-26-015633
2026-05-0720:32 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001437749-26-015621
2026-04-2820:15 ETDEF 14AProxy statementPeriod 2026-06-110001437749-26-013671
2026-02-2621:41 ET10-KAnnual reportPeriod 2025-12-310001437749-26-005891
2026-02-2621:16 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001437749-26-005869
2025-11-0621:41 ET10-QQuarterly reportPeriod 2025-09-300001437749-25-033633

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1401667
Tickers
PBYI
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Accelerated filer<br>Smaller reporting company
Former names
INNOVATIVE ACQUISITIONS CORP (to 2011-10-04)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. Listed shows no prices and gives no investment advice.